Menu Close

Bibliography

Our bibliography includes peer-reviewed publications that were authored by Consortium researchers (highlighted in bold).

  1. Algarin AB, Plazarte GN, Sovich KR, Seeger SD, Li Y, Cohen RA, Striley CW, Goldberger BA, Wang Y, Somboonwit C, Ibañez GE, Spencer EC, Cook RL. Marijuana Use and Health Outcomes in Persons Living With HIV: Protocol for the Marijuana Associated Planning and Long-term Effects (MAPLE) Longitudinal Cohort Study JMIR Res Protoc 2022;11(8):e37153 DOI: 10.2196/37153 PMID: 36040775 PMCID: 9472048.
  2. Alipour Haris G, Sarayani A, Winterstein AG. Letter by Alipour Haris et al Regarding Article, “Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis”. Stroke. 2020 May;51(5): e91. DOI: 10.1161/STROKEAHA.120.029273 Epub 2020 Apr 7. PMID: 32252600.
  3. Brown JDCostales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, Winterstein AG. Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry. J Clin Med. 2020 Apr 18;9(4):1166. DOI: 10.3390/jcm9041166  PMID: 32325769; PMCID: PMC7230351 
  4. Brown JD, Goodin AJ. High risk of bias in medical cannabis and cannabinoid clinical trials dictates the need for cautious interpretation. Med Cannabis Cannabinoids. 2021; 4:63-66. DOI: 10.1159/000514732
  5. Brown JD, Goodin AJ. The prevalence of drivers under the influence of medical cannabis must be considered within proper context. Res Social Adm Pharm. 2019 Nov;15(11):1372-1373. DOI: 10.1016/j.sapharm.2019.01.015  Epub 2019 Jan 28. PMID: 30709730.
  6. Brown JD, Goodin AJ. Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19? Med Cannabis Cannabinoids 2022;5:1-4. DOI: 10.1159/000522472
  7. Brown JD, Rivera KJ, Crespo-Hernandez LY, Doenges MR, Auchey I, Pharm T and Goodin AJ. Natural and Synthetic Cannabinoids: Pharmacology, Uses, and Adverse Drug Events. J Clin Pharmacol. 2021; Aug; 61 Suppl 2:S37-S52. https://doi.org/10.1002/jcph.1871 . PMID: 34396558.
  8. Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019 Jul 8;8(7):989. DOI: 10.3390/jcm8070989 PMID: 31288397; PMCID: PMC6678684  
  9. Brown JD. Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions. J Clin Med. 2020 Mar 27; 9(4):919. doi: 10.3390/jcm9040919 . PMID: 32230864; PMCID: PMC7231229.
  10. Boullosa CC, Vaddiparti K, Lopez-Quintero C, Varma DS, Cook RL. Clinical Decision Making by Medical Marijuana Physicians in Florida: A Qualitative Assessment.  In press, Substance Use and Misuse, 2022.  DOI: 10.1080/10826084.2022.2129995
  11. Costales B, van Boemmel-Wegmann S, Winterstein A, Segal R. Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. J Psychoactive Drugs. 2021 Jan 4:1-10. DOI: 10.1080/02791072.2020.1864069  Epub ahead of print. PMID: 33393877.
  12. Goodin AJ, Wilson DL, Cook RL, Wang Y, Brown J, Winterstein AG. Proceedings of the 2021 Cannabis Clinical Outcomes Research Conference. Med Cannabis Cannabinoids 2021. DOI: 10.1159/000519037
  13. Goodin AJ, Winterstein AGCook RL, Wang Y, Brown JD. Introducing Commentary Series: “Evidence in Context.” Med Cannabis Cannabinoids 2021; 4:61-62. DOI: 10.1159/000512684
  14. Jugl S, Goodin AJ, Brown JD. Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain. Med Cannabis Cannabinoids. 2023 Apr 26;6(1):41-45. DOI: 10.1159/000530251. PMCID: PMC10134049
  15. Jugl S, Okpeku A, Costales B, Morris EJ, Alipour-Haris G, Hincapie-Castillo JM, Stetten NESajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, Winterstein AG, Goodin AJ. A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Med Cannabis Cannabinoids 2021; 4:21-42. DOI: 10.1159/000515069
  16. Jugl SSajdeya R, Morris E, J, Goodin AJ, Brown JD. Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit. Med Cannabis Cannabinoids 2021. DOI: 10.1159/000517154
  17. Muschett M, Brown JD. Profile of Older Users of Medical Cannabis and Cannabinoids. In: Martin, Patel, & Preedy (editors). Medicinal Usage of Cannabis and Cannabinoids. 1st ed. Elsevier. 2022 (In press).
  18. Smolinksi NSajdeya RCook RLWang YWinterstein AG and Goodin AJ. Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference (CCORC) Orlando, FL, USA, May 19-20, 2022. Med Cannabis Cannabinoids 2022;5:142-158. DOI: 10.1159/000527081
  19. Rosenthal M, Pipitone N. Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida. Med Cannabis Cannabinoids 2021; 4:13-20. DOI: 10.1159/000512342 
  20. Roussos-Ross K, Dukharan V, Goodin AJ. Is In-Utero Marijuana Exposure Associated with Childhood Developmental Delay? [20K], Obstetrics & Gynecology: May 2020 – Volume 135 – Issue – p 118S-119S DOI: 10.1097/01.AOG.0000664476.72398.7c
  21. Sajdeya R, Brown JD, Goodin AJ. Perinatal Cannabis Exposures and Autism Spectrum Disorders. Med Cannabis Cannabinoids 2021, 4:67-71.  DOI: 10.1159/000515871
  22. Sajdeya RCook RL. Need to Improve Dose Measurements in Studies of Marijuana Use for Pain. J Acquir Immune Defic Syndr. 2020 Mar 1; 83(3):e23. DOI 10.1097/QAI.0000000000002238 PMID: 32032280
  23. Sajdeya R, Fechtel HJ, Spandau G, Goodin AJ, Brown JD, Jugl SSmolinski NE, Winterstein AG, Cook RL, Wang Y. Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study. Med Cannabis Cannabinoids. 2023 May 9;6(1):46-57. DOI: 10.1159/000530052  PMID: 37261066; PMCID: PMC10228286.
  24. Sajdeya R, Goodin AJ, Tighe PJ. Cannabis use assessment and documentation in healthcare: Priorities for closing the gap. Prev Med. 2021 Sep 8:106798. DOI: 10.1016/j.ypmed.2021.106798  Epub ahead of print. PMID: 34506820.
  25. Sajdeya R, Joseph V, Stetten N, Ibañez G, Wang Y, Powell L, Somboonwit C, Corsi K, Cook RL. Reasons for Marijuana Use and Its Perceived Effectiveness in Therapeutic and Recreational Marijuana Users Among People Living with HIV in Florida. Cannabis. 2021, Volume 4 (1). DOI: 10.26828/cannabis/2021.01.002 
  26. Sajdeya R, Jugl S, Cook RL, Brown JD, Goodin AJ. Clinical Considerations for Cannabis Use and Cardiovascular Health. Med Cannabis Cannabinoids 2022;5:120-127. DOI: 10.1159/000526731
  27. Sajdeya R, Mardini MT, Tighe PJ, Ison RL, Bai C, Jugl S, Hanzhi G, Zandbiglari K, Adiba FI, Winterstein AG, Pearson TA, Cook RL, Rouhizadeh M. Developing and validating a natural language processing algorithm to extract preoperative cannabis use status documentation from unstructured narrative clinical notes. J Am Med Inform Assoc. 2023 May 13:ocad080. DOI: 10.1093/jamia/ocad080  Epub ahead of print. PMID: 37178155.
  28. Sajdeya R, Shavers A, Jean-Jacques J, Costales B, Jugl S, Crump C, Wang Y, Manfio L, Pipitone RN, Rosenthal MS, Winterstein AG, Cook RL. Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida. J Prim Care Community Health. 2021 Jan-Dec; 12: 21501327211042790. doi: 10.1177/21501327211042790. PMID: 34452585; PMCID: PMC8404623.
  29. Smolinski NE, Sajdeya R, Cook RL, Wang Y, Winterstein AG, Goodin AJ. Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference. Med Cannabis Cannabinoids 2022;5:138-141. https://doi.org/10.1159/000527080
  30. Vaddiparti K, Liu Y, Bottari S, Boullosa CC, Zhou Z, Wang Y, Williamson J, Cook RL. Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study. Med Cannabis Cannabinoids. 2023 Nov 13;6(1):160-169. doi: 10.1159/000534710. PMID: 37965569; PMCID: PMC10642978
  31. Wang YJean Jacques J, Li Z, Sibille KT, Cook RL. Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA). Cannabis. 2021 Oct;4(2):69-83. DOI: 10.26828/cannabis/2021.02.006  PMID: 34671723; PMCID: PMC8525881

Last updated July 17th, 2023